Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2008
08/21/2008DE202008007806U1 Substanz zur Behandlung otologischer Störungen Substance for the treatment otologic disorders
08/21/2008DE102007007751A1 Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel New substituted Arylsulfonylglycine, their preparation and their use as medicaments
08/21/2008DE102007007698A1 Verwendung einer hochemulgierten Silikonöl-Emulsion (HSE)zur Herstellung eines Medikamentes Use of a highly emulsified silicone oil emulsion (HSE) for preparing a medicament
08/21/2008DE102007007629A1 Verfahren zur Herstellung von 5-Hydroxymethyl-furfural über 5-Acyloxymethyl-furfural als Zwischenprodukt Process for the preparation of 5-hydroxymethylfurfural on 5-acyloxymethylfurfural as an intermediate
08/21/2008DE102005005397B4 Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms Isolation of N-butyl benzene, synthesis of benzenesulfonamide derivatives as well as using N-butyl benzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostatic hyperplasia and / or prostate carcinoma
08/21/2008CA2728541A1 Crystalline forms of thiazolidinedione compound and its manufacturing method
08/21/2008CA2713977A1 Methods and compositions for the disruption of biofilms
08/21/2008CA2679849A1 Functionally selective alpha2c adrenoreceptor agonists
08/21/2008CA2678575A1 Compounds having a cyclic moiety and compositions for delivering active agents
08/21/2008CA2678535A1 Controlled-release preparation containing cilostazol and process for the preparation thereof
08/21/2008CA2678515A1 Use of ranolazine for the treatment of cardiovascular diseases
08/21/2008CA2678407A1 A pharmaceutical composition comprising extracts of stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo
08/21/2008CA2678382A1 New substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions
08/21/2008CA2678363A1 Drug resistance reversal in neoplastic disease
08/21/2008CA2678358A1 Cancer treatment method
08/21/2008CA2678332A1 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
08/21/2008CA2678325A1 Use of ranolazine for the treatment of non-coronary microvascular diseases
08/21/2008CA2678319A1 Use of ranolazine for the treatment of coronary microvascular diseases
08/21/2008CA2678191A1 Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure
08/21/2008CA2678127A1 Tgf-beta stimulant and further agent to reduce side effects
08/21/2008CA2678077A1 2-aminopyrimidine modulators of the histamine h4 receptor
08/21/2008CA2678072A1 Functionally selective alpha2c adrenoreceptor agonists
08/21/2008CA2678069A1 Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
08/21/2008CA2678036A1 Functionally selective alpha2c adrenoreceptor agonists
08/21/2008CA2677978A1 Salts forms of 4-phenylamino quinazoline derivative
08/21/2008CA2677931A1 Use of ranolazine for the treatment of cardiovascular diseases
08/21/2008CA2677905A1 Pharmaceutical composition comprising pyrazine derivatives and neuraminidase inhibitors for treating influenza infections
08/21/2008CA2677856A1 Pharmaceutical carrier composition and pharmaceutical composition
08/21/2008CA2677842A1 Pharmaceutical composition comprising microparticle oily suspension
08/21/2008CA2677822A1 Antihypertensive drug combination
08/21/2008CA2677818A1 The secreted protein ccdc80 regulates adipocyte differentiation
08/21/2008CA2677813A1 Method of treating cell proliferative disorders using growth hormone secretagogues
08/21/2008CA2677783A1 Compositions and methods for treatment of liver disease
08/21/2008CA2677769A1 Therapeutic agent for urinary excretion disorder
08/21/2008CA2677747A1 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
08/21/2008CA2677736A1 Fused ring compounds as partial agonists of ppar-gamma
08/21/2008CA2677715A1 Use of chitosans to increase nail growth rate
08/21/2008CA2677703A1 Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
08/21/2008CA2677678A1 3,4-dihydro-1,4-benzoxazine, 3, 4-dihydro-1, 4-benzothiazine and 1,2,3,4-tetrahydro-quinoxaline derivatives as alpha2c adrenoreceptor agonists
08/21/2008CA2677651A1 Combinations of therapeutic agents for treating cancer
08/21/2008CA2677649A1 Bioavailable formulations of heterocyclic compounds
08/21/2008CA2677588A1 Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases
08/21/2008CA2677281A1 Transoral dosage forms comprising sufentanil and naloxone
08/21/2008CA2677269A1 Anhydrous crystalline vinflunine salts, method of preparation and use thereof as a drug and means of vinflunine purification
08/21/2008CA2676944A1 2-aminooxazolines as taar1 ligands
08/21/2008CA2676920A1 Piperidine derivatives
08/21/2008CA2676736A1 Pyridyl-triazolopyrimidine derivative or its salt, pesticide containing it and its production process
08/21/2008CA2676715A1 Piperazine derivatives for treatment of ad and related conditions
08/21/2008CA2676607A1 Improved stability in vitamin and mineral supplements
08/21/2008CA2676581A1 Heterocyclic derivatives as m3 muscarinic receptors
08/21/2008CA2676352A1 Pharmaceutical compositions and methods for ccr5 antagonists
08/21/2008CA2676259A1 Use of chitosans for the treatment of nail inflammatory diseases
08/21/2008CA2676154A1 Pyrazole derivatives as 11-beta-hsd1 inhibitors
08/21/2008CA2675793A1 Reducing post-operative adhesion formation with intraperitoneal glutamine
08/21/2008CA2675568A1 Dermal film-forming liquid formulations for drug release to skin
08/21/2008CA2675200A1 Substituted pyridine n-oxide herbicides
08/21/2008CA2674773A1 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
08/21/2008CA2674752A1 3,4-dihydropyrrolo[1,2-a]pyrazin-1-yl amines useful as fast dissociating dopamine 2 receptor antagonists
08/21/2008CA2674100A1 Use of neuroprotective compounds for obtaining drugs for treating neurodegenerative diseases
08/21/2008CA2674097A1 New aminopyrrolo[1,2-.alpha.]indole et aminopyridazino[1,6-.alpha.]indole derivatives, method for preparing the same and pharmaceutical compositions containing the same
08/21/2008CA2674094A1 Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form
08/21/2008CA2674087A1 6' substituted compounds having 5-ht6 receptor affinity
08/21/2008CA2674083A1 Novel triazabenzo[.alpha.]naphtho[2,l,8-cde]azulene derivatives, method for preparing the same and pharmaceutical compositions containing the same
08/21/2008CA2673573A1 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
08/21/2008CA2673534A1 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular ikk inhibitors
08/21/2008CA2673532A1 New phenyl-(4-phenyl-pyrimidin-2-yl)-amines derivatives, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors
08/21/2008CA2672959A1 New n, n'- 2,4-dianilinopyrimidine derivatives, preparation thereof as drugs, pharmaceutical compositions essentially as ikk inhibitors
08/21/2008CA2672955A1 New 2, 4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors
08/21/2008CA2621452A1 Stent and method for reducing tissue damage after ischemic injury with thymosin b4
08/20/2008EP1959013A1 Human circulating virus inhibitory peptide (VRIP) and its use
08/20/2008EP1959010A2 Apoptosis-specific eif-5A and polynucleotides encoding same
08/20/2008EP1958965A2 Agonist antibodies to a musk receptor, and their therapeutic uses
08/20/2008EP1958963A1 Oxygen-carrying blood substitute preparations
08/20/2008EP1958956A2 Peptidomimetic protease inhibitors
08/20/2008EP1958951A1 Phosphine transition metal complex, method for producing same and antitumor agent containing same
08/20/2008EP1958949A1 Therapeutic agent for corneal/conjuctival disease
08/20/2008EP1958947A1 Inhibitors of phosphodiesterase type 4
08/20/2008EP1958941A1 Oxazolidinones and their use as hypocholesterolemic agents
08/20/2008EP1958939A2 Pyrazole-amine compounds for the treatment of neurodegenerative disorders
08/20/2008EP1958937A1 Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same
08/20/2008EP1958934A1 Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents
08/20/2008EP1958666A1 Heterocyclic-substituted alkanamides as therapeutic compounds
08/20/2008EP1958642A1 Regulation of cell growth by MUC1
08/20/2008EP1958639A1 Use of chitosans for the treatment of nail inflammatory diseases
08/20/2008EP1958638A1 Use of chitosans to increase nail growth rate
08/20/2008EP1958637A1 Pharmaceutical composition for the treatment of IL-8 mediated diseases
08/20/2008EP1958636A1 Pharmaceutical compositions containing combined antidiabetic substances for use in type 2 diabetes mellitus
08/20/2008EP1958635A1 Treatment
08/20/2008EP1958634A2 Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease
08/20/2008EP1958633A2 Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin
08/20/2008EP1958632A1 Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases
08/20/2008EP1958631A1 Novel triazole derivatives as ligands of G-protein coupled receptors
08/20/2008EP1958630A1 Antibacterial combination of a tricyclic carbapenem and an antibiotic
08/20/2008EP1958629A1 A transdermal fluid comprising tocotrienol
08/20/2008EP1958628A1 Combination of immediately liberated drospirenone with a modified releasing formulation containing 8-prenylnaringenin for use in oral contraception and hormone replacement therapy
08/20/2008EP1958627A2 Use of certain menthyl-3-oxocarbonic acid esters as physiological cooling agents
08/20/2008EP1958626A1 Method for inactivating viruses by addition of slightly acidic arginine
08/20/2008EP1958625A1 Enteric coate bead comprising ixabepilone and preparation thereof
08/20/2008EP1958621A2 Drug detoxification protocol using microdosing
08/20/2008EP1958616A1 Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof
1 ... 3124 3125 3126 3127 3128 3129 3130 3131 3132 3133 3134 3135 3136 3137 3138 3139 3140 3141 3142 3143 3144 ... 7860